請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70376
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 武敬和(Ching-Ho Wu) | |
dc.contributor.author | Gao-Chi Chiang | en |
dc.contributor.author | 江高旗 | zh_TW |
dc.date.accessioned | 2021-06-17T04:26:52Z | - |
dc.date.available | 2023-08-15 | |
dc.date.copyright | 2018-08-15 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-14 | |
dc.identifier.citation | 1. Pao, L.-H., et al., In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. Drug Metabolism and Disposition, 2005. 33(3): 395-402.
2. Mathews, K.A., Pain assessment and general approach to management. Veterinary Clinics of North America: Small Animal Practice, 2000. 30(4): 729-755. 3. Williams, A.C.d.C. and K.D. Craig, Updating the definition of pain. Pain, 2016. 157(11): 2420-2423. 4. Epstein, M.E., et al., 2015 AAHA/AAFP pain management guidelines for dogs and cats. Journal of Feline Medicine and Surgery, 2015. 17(3): 251-272. 5. Reid, J., et al., Pain Assessment In Animals. In Practice, 2013. 35(2): 51-56. 6. Pasternak, G.W., The opiate receptors. 2011: Springer. 7. Hardman, J., L. Limbird, and P. Molinoff, Opioid analgesics. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 2001: 569-605. 8. Gunion, M.W., A.M. Marchionne, and C.T. Anderson, Use of the mixed agonist–antagonist nalbuphine in opioid based analgesia. Acute Pain, 2004. 6(1): 29-39. 9. Mogil, J.S., et al., Functional antagonism of μ-, δ-and κ-opioid antinociception by orphanin FQ. Neuroscience Letters, 1996. 214(2-3): 131-134. 10. Morgan, M.M., et al., Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ. Neuroreport, 1997. 8(16): 3431-3434. 11. De Souza, E.B., W.K. Schmidt, and M.J. Kuhar, Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. Journal of Pharmacology and Experimental Therapeutics, 1988. 244(1): 391-402. 12. Woolf, C.J., What is this thing called pain? The Journal of Clinical Investigation, 2010. 120(11): 3742-3744. 13. Crompton, S., Reviewing pain assessment and scoring models in cats and dogs–part one. Veterinary Nurse Times, 2014. 14. Holton, L., et al., Development of a behaviour-based scale to measure acute pain in dogs. The Veterinary Record, 2001. 148(17): 525-531. 15. Holton, L., et al., Relationship between physiological factors and clinical pain in dogs scored using a numerical rating scale. Journal of Small Animal Practice, 1998. 39(10): 469-474. 16. Cambridge, A.J., et al., Subjective and objective measurements of postoperative pain in cats. Journal of the American Veterinary Medical Association, 2000. 217(5): 685-690. 17. Anil, S.S., L. Anil, and J. Deen, Challenges of pain assessment in domestic animals. Journal of the American Veterinary Medical Association, 2002. 220(3): 313-319. 18. Brondani, J.T., et al., Validation of the English version of the UNESP-Botucatu multidimensional composite pain scale for assessing postoperative pain in cats. BMC Veterinary Research, 2013. 9(1): 143. 19. Reid, J., et al., Development of the short-form Glasgow Composite Measure Pain Scale (CMPS-SF) and derivation of an analgesic intervention score. Animal Welfare, 2007. 16: 97. 20. Verwaerde, P. and C. Estrade, Vade-mecum d'anesthésie des carnivores domestiques. 2005: Éd. Med'com. 21. Lawler, D.F., et al., Influence of lifetime food restriction on causes, time, and predictors of death in dogs. Journal of the American Veterinary Medical Association, 2005. 226(2): 225-231. 22. Brown, D.C., et al., Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. American Journal of Veterinary Research, 2007. 68(6): 631-637. 23. Brown, D.C., et al., Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. Journal of the American Veterinary Medical Association, 2008. 233(8): 1278-1283. 24. Hielm-Björkman, A.K., H. Rita, and R.-M. Tulamo, Psychometric testing of the Helsinki chronic pain index by completion of a questionnaire in Finnish by owners of dogs with chronic signs of pain caused by osteoarthritis. American Journal of Veterinary Research, 2009. 70(6): 727-734. 25. Wiseman-Orr, M.L., et al., Validation of a structured questionnaire as an instrument to measure chronic pain in dogs on the basis of effects on health-related quality of life. American Journal of Veterinary Research, 2006. 67(11): 1826-1836. 26. Reid, J., et al., Development, validation and reliability of a web‐based questionnaire to measure health‐related quality of life in dogs. Journal of Small Animal Practice, 2013. 54(5): 227-233. 27. Slingsby, L.S., P.M. Taylor, and J.C. Murrell, A study to evaluate buprenorphine at 40 μg kg− 1 compared to 20 μg kg− 1 as a post‐operative analgesic in the dog. Veterinary Anaesthesia and Analgesia, 2011. 38(6): 584-593. 28. Fox, S., et al., The effects of ovariohysterectomy plus different combinations of halothane anaesthesia and butorphanol analgesia on behaviour in the bitch. Research in Veterinary Science, 2000. 68(3): 265-274. 29. Grint, N.J., et al., Assessment of the influence of surgical technique on postoperative pain and wound tenderness in cats following ovariohysterectomy. Journal of Feline Medicine and Surgery, 2006. 8(1): 15-21. 30. Ready, L.B., Patient-controlled analgesia—does it provide more than comfort? Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 1990. 37(7): 719-721. 31. Firth, A.M. and S.L. Haldane, Development of a scale to evaluate postoperative pain in dogs. Journal of the American Veterinary Medical Association, 1999. 214(5): 651-659. 32. Gaynor, J., et al., Effect of perioperative oral carprofen on postoperative pain in dogs undergoing surgery for stabilization of ruptured cranial cruciate ligaments. Veterinary Therapeutics, 2002. 3: 425-434. 33. Vadivelu, N., S. Mitra, and D. Narayan, Recent advances in postoperative pain management. The Yale Journal of Biology and Medicine, 2010. 83(1): 11. 34. Wu, C.L. and S.N. Raja, Treatment of acute postoperative pain. The Lancet, 2011. 377(9784): 2215-2225. 35. Hu, X., et al., Tolfenamic acid and meloxicam both provide an adequate degree of postoperative analgesia in dogs undergoing ovariohysterectomy. Veterinarni Medicina, 2017. 62(6). 36. Gramke, H.-F., et al., The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. The Clinical journal of pain, 2007. 23(6): 543-548. 37. Curry, S.L., S.M. Cogar, and J.L. Cook, Nonsteroidal antiinflammatory drugs: a review. Journal of the American Animal Hospital Association, 2005. 41(5): 298-309. 38. Mathews, K.A., Non‐steroidal anti‐inflammatory analgesics: a review of current practice. Journal of Veterinary Emergency and Critical Care, 2002. 12(2): 89-97. 39. Deneuche, A.J., et al., Analgesic comparison of meloxicam or ketoprofen for orthopedic surgery in dogs. Veterinary Surgery, 2004. 33(6): 650-660. 40. Monteiro‐Steagall, B., P. Steagall, and B. Lascelles, Systematic review of nonsteroidal anti‐inflammatory drug‐induced adverse effects in dogs. Journal of Veterinary Internal Medicine, 2013. 27(5): 1011-1019. 41. Schmidt, H. Efficacy and safety of meloxicam in the control of peri-operative pain in the dog. in Proceedings of the Recent Advances in Non-Steroidal Anti-Inflammatory Therapy in Small Animals Symposium, Paris, France. 1999. 42. Khajuria, A., M. Bhadwal, and A. Gupta, Anti-nociceptive Efficacy of Carprofen and Meloxicam in Ovario-hysterectomized Dogs. Journal of Animal Research, 2017. 7(5): 973-977. 43. Montoya, L., et al., A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. Veterinary Research Communications, 2004. 28(5): 415-428. 44. Mathews, K.A., et al., Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. American Journal of Veterinary Research, 2001. 62(6): 882-888. 45. Gritsenko, K., et al., Multimodal therapy in perioperative analgesia. Best Practice and Research Clinical Anaesthesiology, 2014. 28(1): 59-79. 46. Buvanendran, A. and J.S. Kroin, Multimodal analgesia for controlling acute postoperative pain. Current Opinion in Anesthesiology, 2009. 22(5): 588-593. 47. Zeng, Z., et al., A comparision of nalbuphine with morphine for analgesic effects and safety: Meta-analysis of randomized controlled trials. Scientific Reports, 2015. 5. 48. Yeh, C.-Y., et al., Sebacoyl Dinalbuphine Ester Extended-release Injection for Long-acting Analgesia: A Multicenter, Randomized, Double-Blind, And Placebo-controlled Study in Hemorrhoidectomy Patients. The Clinical Journal of Pain, 2017. 33(5): 429-434. 49. Glare, P. and T. Walsh, Clinical pharmacokinetics of morphine. Therapeutic Drug Monitoring, 1991. 13(1): 1-23. 50. Muldoon, S., et al., Plasma histamine and hemodynamic responses following administration of nalbuphine and morphine. Agents and Actions, 1984. 15(3-4): 229-234. 51. Thomas, D., et al., Effects of central administration of opioids on facial scratching in monkeys. Brain Research, 1992. 585(1-2): 315-317. 52. Murphy, D., et al., Opioid-induced Delay in Gastric Emptying A Peripheral Mechanism in Humans. Anesthesiology: The Journal of the American Society of Anesthesiologists, 1997. 87(4): 765-770. 53. Shook, J.E., et al., Peptide opioid antagonist separates peripheral and central opioid antitransit effects. Journal of Pharmacology and Experimental Therapeutics, 1987. 243(2): 492-500. 54. Li, C.-J., et al., In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release. International Journal of Pharmaceutics, 2017. 531(1): 306-312. 55. Huang, W.C., et al., Pharmacokinetics of dinalbuphine sebacate and nalbuphine in Human after Intramuscular Injection of dinalbuphine sebacate in an Extended‐Release Formulation. Biopharmaceutics and Drug Disposition, 2017. 56. Logash, M., et al., Nalbuphine: some aspects of the research and applications. Medical Studies/Studia Medyczne, 2017. 33(2): 146-154. 57. Schmidt, W.K., et al., Nalbuphine. Drug and Alcohol Dependence, 1985. 14(3-4): 339-362. 58. Stringer, R.A., et al., Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metabolism and Disposition, 2009. 37(5): 1025-1034. 59. Lo, M., et al., The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. European Journal of Clinical Pharmacology, 1987. 33(3): 297-301. 60. Gal, T.J., C.A. DiFazio, and J. Moscicki, Analgesic and respiratory depressant activity of nalbuphine: a comparison with morphine. Anesthesiology, 1982. 57(5): 367-374. 61. Romagnoli, A. and A.S. Keats, Ceiling effect for respiratory depression by nalbuphine. Clinical Pharmacology & Therapeutics, 1980. 27(4): 478-485. 62. Pugh, G. and G. Drummond, A dose-response study with nalbuphine hydrochloride for pain in patients after upper abdominal surgery. BJA: British Journal of Anaesthesia, 1987. 59(11): 1356-1363. 63. Fournier, R., et al., Onset and offset of intrathecal morphine versus nalbuphine for postoperative pain relief after total hip replacement. Acta Anaesthesiologica Scandinavica, 2000. 44(8): 940-945. 64. Culebras, X., et al., Advantages of intrathecal nalbuphine, compared with intrathecal morphine, after cesarean delivery: an evaluation of postoperative analgesia and adverse effects. Anesthesia & Analgesia, 2000. 91(3): 601-605. 65. Houlihan, K., et al., Excessive morphine requirements after pre-hospital nalbuphine analgesia. Emergency Medicine Journal, 1999. 16(1): 29-31. 66. Minai, F. and F. Khan, A comparison of morphine and nalbuphine for intraoperative and postoperative analgesia. Journal of the Pakistan Medical Association, 2003. 53(9): 391-395. 67. Van den Berg, A., et al., Analgesics and ENT surgery. A clinical comparison of the intraoperative, recovery and postoperative effects of buprenorphine, diclofenac, fentanyl, morphine, nalbuphine, pethidine and placebo given intravenously with induction of anaesthesia. British Journal of Clinical Pharmacology, 1994. 38(6): 533. 68. Yeh, Y.-C., et al., Combination of opioid agonist and agonist–antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. British Journal of Anaesthesia, 2008. 101(4): 542-548. 69. Akshat, S., et al., Morphine versus nalbuphine for open gynaecological surgery: a randomized controlled double blinded trial. Pain Research and Treatment, 2014. 70. Jannuzzi, R.G., Nalbuphine for treatment of opioid-induced pruritus: a systematic review of literature. The Clinical Journal of Pain, 2016. 32(1): 87-93. 71. Charuluxananan, S., et al., Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Anesthesia & Analgesia, 2001. 93(1): 162-165. 72. Cohen, S.E., et al., Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesthesia and Analgesia, 1992. 75(5): 747-752. 73. Somrat, C., et al., Optimal Dose of Nalbuphine for Treatment of Intrathecal‐Morphine Induced Pruritus after Caesarean Section. Journal of Obstetrics and Gynaecology Research, 1999. 25(3): 209-213. 74. Davies, G. and R. From, A Blinded Study Using Nalbuphine for Prevention of Pruritus Induced by Epidural Fentanyl. Obstetric Anesthesia Digest, 1989. 9(2): 101. 75. Teter, K.A., G. Viellion, and E.M. Keating, Patient controlled analgesia and GI dysfunction. Orthopedic Nursing, 1990. 9(4): 51-56. 76. Jaffe, R.S., et al., Nalbuphine antagonism of fentanyl-induced ventilatory depression: a randomized trial. Anesthesiology, 1988. 68(2): 254-260. 77. Blaise, G., et al., Nalbuphine produces side-effects while reversing narcotic-induced respiratory depression. Anesthesia and Analgesia, 1986. 65: S19. 78. Hu, O.Y.-P. and C.-C. Chang, Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form. 2014, Google Patents. 79. Pao, L.-H., et al., High-performance liquid chromatographic method for the simultaneous determination of nalbuphine and its prodrug, sebacoyl dinalbuphine ester, in dog plasma and application to pharmacokinetic studies in dogs. Journal of Chromatography B: Biomedical Sciences and Applications, 2000. 746(2): 241-247. 80. Leinweber, F.-J., Possible physiological roles of carboxylic ester hydrolases. Drug Metabolism Reviews, 1987. 18(4): 379-439. 81. Williams, F.M., Clinical significance of esterases in man. Clinical Pharmacokinetics, 1985. 10(5): 392-403. 82. Freitas, S., H.P. Merkle, and B. Gander, Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. Journal of Controlled Release, 2005. 102(2): 313-332. 83. Jiang, W., et al., Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Advanced Drug Delivery Reviews, 2005. 57(3): 391-410. 84. Chien, Y.W., Long-acting parenteral drug formulations. Journal of Parenteral Science and Technology, 1981. 35(3): 106. 85. Larsen, S.W. and C. Larsen, Critical factors influencing the in vivo performance of long-acting lipophilic solutions—impact on in vitro release method design. American Association of Pharmaceutical Scientists, 2009. 11(4): 762-770. 86. Huang, P.W., et al., Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic study in humans. Biomedical Chromatography, 2013. 27(7): 831-837. 87. Zhang, S., et al., Comparison of the effects of nefopam and tramadol on postoperative analgesia in dogs undergoing ovariohysterectomy. Veterinarni Medicina, 2017. 62(3). 88. Tallant, A., et al., Comparison of intraoperative and postoperative pain during canine ovariohysterectomy and ovariectomy. The Canadian Veterinary Journal, 2016. 57(7): 741. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70376 | - |
dc.description.abstract | 鴉片類藥物常用於術後疼痛控制中,而嗎啡(morphine)是最常使用之標準鴉片類止痛藥。然而,使用嗎啡時也需要考量鴉片類藥物相關之副作用與其相對較短的半衰期。Nalbuphine是一種kappa-受器致效劑與部分mu-受器拮抗劑,在提供相當止痛效果的同時,也可以降低嗎啡相關的副作用。Sebacoyl dinalbulphine ester (SDE)則是一種以nalbuphine與diester合成的前驅藥物,因為具有高脂溶性的特性,因此可以延長nalbuphine在肌肉注射時的作用時間。本實驗為一篇隨機、觀察者盲性、使用活性對照組的研究,以評估單一肌肉注射SDE在犬隻子宮卵巢切除術術後疼痛控制中的安全性、效力與藥物動力學。實驗共納入32隻安排進行子宮卵巢切除術之犬隻,並將其隨機分為三個治療組別(meloxicam 0.1 mg/kg, SDE15 mg/kg and SDE 30 mg/kg),以Canine acute pain scale (CAPS)和 short form of the Glasgow composite pain scale (GCPS)評估其術後疼痛程度,並記錄任何不良反應。
實驗結果顯示,三個治療組別間在各個時間點的CAPS與GCPS評分皆沒有顯著差異。而儘管沒有顯著差異,但高劑量SDE組擁有相對較好的疼痛控制,其代表SDE造成的止痛效果可能具有劑量依賴性的特性。在低劑量SDE與高劑量SDE組中,沒有任何犬隻在手術後24小時內需要給予救援止痛藥。實驗中沒有觀察到任何嚴重的不良反應。在三個治療組別中,過度流涎與噁心(28.1%)是最常見藥物相關的不良反應。在高劑量SDE組別中,有一個實驗病患(8.3 %)在給藥後2小時出現了注射部位反應,但在術後24小時後自行緩解。總結而言,在適當的劑量下,SDE可以在犬隻子宮卵巢切除術術後提供良好的止痛,並擁有良好的耐受性。 | zh_TW |
dc.description.abstract | Opioids are commonly used in postoperative pain management and morphine is the mostly used and standard opioid analgesic drug. However, opioid related adverse effects and relative short elimination half life should be concerned. Nalbuphine, a potent kappa-receptor agonist and partial mu-receptor antagonist, could reduce the risk of adverse effect associated with morphine and provide comparable analgesic effect. Sebacoyl dinalbulphine ester (SDE) is a synthetic diester prodrug of nalbuphine which has high lipophilicity that prolongs the duration of nalbuphine after intramuscular (IM) injection. A randomized, observer blinded, single dose, active-controlled study was performed to evaluate the safety, efficacy and pharmacokinetics of IM SDE for dogs in post-ovariohysterectomy pain management. Thirty-two dogs scheduled for ovariohysterectomy were enrolled and randomized into 3 treatment groups (meloxicam 0.1 mg/kg, SDE15 mg/kg and SDE 30 mg/kg). Canine acute pain scale (CAPS) and short form of the Glasgow composite pain scale (GCPS) were used to assess postoperative pain. Any adverse events were recorded.
The results revealed that there was no significant difference of CAPS and GCPS between the 3 treatment groups at any time point. High dose SDE group yielded better pain control than low dose SDE and indicated that the analgesia provided by SDE is dose-dependent. No dogs in either low or high dose SDE required rescue analgesic in first 24 hours post-operatively. No serious adverse event was reported. Hypersalivation and nausea (28.1%) was the most common drug-related adverse event among the 3 treatment groups. Only 1 dog (8.3%) in high dose SDE had mild muscle swelling at the injection site and resolved spontaneously after 24 hours post-operatively. In conclusion, SDE is generally well-tolerated and a fine analgesic for pain management during the first 24 hours in dogs following ovariohysterectomy by using an adequate dose. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T04:26:52Z (GMT). No. of bitstreams: 1 ntu-107-R05643005-1.pdf: 2282844 bytes, checksum: a57835eb333eb6382ff3e3f038a62fa1 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書…………………………………………………...…...ii
誌謝……………………………………………………………………….iii 中文摘要………………………………………………………………… iv 英文摘要………………………………………………………………......v 圖目錄………………………………………………………………….....iv 表目錄…………………………………………………………………….x 第一章 文獻探討與研究目的………………………………………….1 第一節 疼痛的定義與生理機制…………………………………….1 第二節 疼痛的種類、辨識與評估………………………………….2 第三節 疼痛控制的優點與方式…………………………………….8 第四節 鴉片類藥物的使用限制……………………………...……10 第五節 Nalbuphine的藥物特性………………………………....…11 第六節 SDE的藥物特性…………………………………………...14 第七節 研究目標……………………………………………………17 第二章 材料與方法……………………………………………………18 第一節 實驗設計……………………………………………………18 第二節 實驗病患選擇與定義………………………………………19 第三節 治療藥物……………………………………………………20 第四節 實驗評估……………………………………………………21 第五節 數據整理與統計方法………………………………………25 第三章 結果……………………………………………………………27 第一節 實驗病患分析………………………………………………27 第二節 效力分析……………………………………………………36 第三節 安全性分析…………………………………………………45 第四節 藥物動力學分析……………………………………………67 第四章 討論……………………………………………………………70 第一節 實驗病患分析………………………………………………70 第二節 效力分析……………………………………………………70 第三節 安全性分析…………………………………………………73 第四節 藥物動力學分析……………………………………………76 第五節 研究限制……………………………………………………76 第六節 結論…………………………………………………………78 第五章 參考文獻……….………………….…………………………....79 附錄 一…………………………………………………………………..86 附錄 二…………………………………………………………………..87 | |
dc.language.iso | zh-TW | |
dc.title | 評估單一劑量Sebacoyl Dinalbulphine Ester肌肉注射在犬隻子宮卵巢切除術術後疼痛控制之安全性、效力與藥物動力學: 隨機、觀察者盲性與使用活性對照組之研究 | zh_TW |
dc.title | Safety, Efficacy and Pharmacokinetics of Single Dose Intramuscular Sebacoyl Dinalbulphine Ester for Dogs in Post-Ovariohysterectomy Pain management: A Randomized, Observer Blinded, and Active Control Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張雅珮,孫維仁,劉振軒 | |
dc.subject.keyword | Sebacoyl Dinalbulphine Ester,nalbuphine,疼痛控制,狗,子宮卵巢切除術,short form of the Glasgow composite pain scale,Canine acute pain scale, | zh_TW |
dc.subject.keyword | Sebacoyl Dinalbulphine Ester,nalbuphine,pain management,dogs,ovariohysterectomy,short form of the Glasgow composite pain scale,Canine acute pain scale, | en |
dc.relation.page | 87 | |
dc.identifier.doi | 10.6342/NTU201803246 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-14 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。